Cargando…
Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins
The clinical utility of rifamycins against non-tuberculous mycobacterial (NTM) disease is limited by intrinsic drug resistance achieved by ADP-ribosyltransferase Arr. By blocking the site of ribosylation, we recently optimized a series of analogs with substantially improved potency against Mycobacte...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580999/ https://www.ncbi.nlm.nih.gov/pubmed/37681986 http://dx.doi.org/10.1128/spectrum.01900-23 |